Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 3.83Nectar Lifescience Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strengths in solvency and profitability, driven by a solid equity base and returns on capital employed, alongside prudent capital expenditure management. However, it faces challenges in liquidity, growth, and efficiency, which are areas needing attention. The absence of revenue growth and low coverage ratios are significant concerns. While the company maintains a strong equity position, improvements in operational efficiency and revenue generation are crucial for sustained financial health and future prospects.
Health Score : 3.83Nectar Lifescience Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strengths in solvency and profitability, driven by a solid equity base and returns on capital employed, alongside prudent capital expenditure management. However, it faces challenges in liquidity, growth, and efficiency, which are areas needing attention. The absence of revenue growth and low coverage ratios are significant concerns. While the company maintains a strong equity position, improvements in operational efficiency and revenue generation are crucial for sustained financial health and future prospects.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-4.11
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
-0.80
P/B RATIO
0.40
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
102.86
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-0.33
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹12.13 as on Sep 1, 2026.
Growth Score : 2.00The company's growth ratios are generally poor. The absence of revenue and net income growth, combined with negative growth in operating profit, earnings per share, and assets, indicates significant challenges in expanding its business. This suggests a need for strategic initiatives to stimulate growth and improve financial performance. Current trends pose a risk to future sustainability.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RatePoorNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 8.05 | -8.71 | 10.66 | -1.07 | -99.88 |
| Operating Profit Growth Rate | 45.87 | -66.67 | 186.79 | -119.74 | -96.67 |
| Earnings Per Share (EPS) Growth | 134.25 | -196.43 | 120.37 | -2404.55 | -197.44 |
| Asset Growth Rate | 0.13 | -8.45 | 0.09 | -6.57 | -69.61 |
| Net Income Growth Rate | 134.25 | -196 | 120.83 | -2380 | -157.02 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 2 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 3 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 4 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 5 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 6 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 60.35 | Neutral | 7.00 | 1.40 | 4.00 |
| 7 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 8 | BPL Ltd | 5.46 | -28.58 | Neutral | -4.82 | -1.69 | -8.55 |
| 9 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 10 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 11 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
| 12 | PANCHSHEEL | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Quarterly Report⬤23rd Jan 26
Quarterly Financial Results Q3 FY 2025-26
BEARISH SENTIMENT
Nectar Lifescience Ltd. (NECLIFE) is an integrated pharmaceutical company based in India. It specializes in manufacturing Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and Menthol & derivatives. The company serves both domestic and international markets, focusing on key therapeutic segments and leveraging its R&D capabilities.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Nectar Lifescience Ltd's P/E ratio (TTM) is -4.11, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Nectar Lifescience Ltd's P/B ratio is 0.40, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Nectar Lifescience Ltd's P/S ratio is 102.86, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Nectar Lifescience Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Nectar Lifescience Ltd's EV/EBITDA ratio is -0.33.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Nectar Lifescience Ltd's ROE is -50.34%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Nectar Lifescience Ltd's ROA is -9.49%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Nectar Lifescience Ltd's ROCE is -5%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Nectar Lifescience Ltd's operating margin is -2950%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Nectar Lifescience Ltd's net margin is -14650%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Nectar Lifescience Ltd's current ratio is 12.92.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Nectar Lifescience Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Nectar Lifescience Ltd's interest coverage ratio is -7.97.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Nectar Lifescience Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Nectar Lifescience Ltd's EPS is -197.44.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹12.13. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1995
Headquarters: Chandigarh, Punjab
Core Offerings: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), Menthol & Derivatives, Phyto-pharmaceuticals
Stock Listing: NSE (NECLIFE), BSE (532649)
Promoter: Sanjiv Goyal / Nectar Lifescience Ltd.
Nectar Lifescience Ltd. was founded in 1995. Initially, the company established itself as a significant player in the bulk drug (API) manufacturing segment. Over the years, it expanded its operations to include pharmaceutical formulations and diversified into the Menthol & Allied products segment. The company has continuously invested in R&D and manufacturing infrastructure to enhance its product portfolio and global presence.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | Approx. 55-60% | Operating Profit |
| Finished Dosage Forms (FDFs) | Approx. 20-25% | Operating Profit |
| Menthol & Derivatives | Approx. 15-20% | Operating Profit |
Active Pharmaceutical Ingredients (APIs): Manufactures a wide range of APIs across various therapeutic areas, including anti-infectives, cephalosporins, and other high-value intermediates, catering to global markets.
Finished Dosage Forms (FDFs): Focuses on formulation development and manufacturing, offering products in therapeutic segments like anti-infectives, cardiology, and gastroenterology for domestic and international distribution.
Menthol & Derivatives: Engaged in the production of menthol and its various derivatives, serving industries such as pharmaceuticals, food & beverages, and personal care.
Sanjiv Goyal - Chairman & Managing Director. As the founder, he has been instrumental in shaping the company's vision, strategic direction, and growth since its inception.
Nectar Lifescience USA Inc.
Nectar Lifescience (Shanghai) Trading Co. Ltd.
No major recent corporate actions on record (such as bonus issues, rights issues, or significant M&A activities in the last 3-5 years). The company had a stock split in 2015 and a rights issue in 2011.
The Nectar Lifescience Ltd share price today is ₹12.13 on NSE (NECLIFE), as of 26 Sept 2026.
As of 26 Sept 2026, Nectar Lifescience Ltd share price is ₹12.13, with previous close ₹12.13. Today's range is ₹12.13 to ₹12.13. The 52-week range is ₹9.30 to ₹22.40.
As of today, Nectar Lifescience Ltd's market cap is ₹205.72 crore (Small Cap).
Nectar Lifescience Ltd's current P/E ratio is -4.11, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 36.50.
Nectar Lifescience Ltd's current P/B ratio is 0.40.
Nectar Lifescience Ltd's current dividend yield is N/A. Last dividend of ₹0.10 per share was declared on 20-Sep-2023.
Nectar Lifescience Ltd's EPS (TTM) is ₹-197.44.
Nectar Lifescience Ltd. (NECLIFE) is an integrated pharmaceutical company based in India. It specializes in manufacturing Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and Menthol & derivatives. The company serves both domestic and international markets, focusing on key therapeutic segments and leveraging its R&D capabilities.
Nectar Lifescience Ltd is promoted by Sanjiv Goyal / Nectar Lifescience Ltd., holding 51.84% as of 26 Sept 2026.
Nectar Lifescience Ltd is listed on NSE (NECLIFE) and BSE (532649). Its next quarterly results are expected on Q1 FY25 (July/August 2024).
Cash Earnings Per Share (Cash EPS)
